Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease
Respir Res. 2017 Aug 21;18(1):158.
doi: 10.1186/s12931-017-0638-2.
1 Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA. [email protected].
2 Department of Medicine, University of Modena and Reggio Emilia, NOCSAE, Modena, Italy.
3 Clinical Research Institute of Southern Oregon, Medford, OR, USA.
4 Spartanburg Medical Research, Spartanburg, NC, USA.
5 American Health Research, Charlotte, NC, USA.
6 Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany.
7 Department of Medicine, Christian-Albrechts University Kiel, Kiel, MI, USA.
8 Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.
9 Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College; New York-Presbyterian Hospital/Weill Cornell MedicalCenter, New York, NY, USA.
10 Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
11 Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA.
12 Pearl Therapeutics Inc., Durham, NC, USA.
13 Pearl Therapeutics Inc., Redwood City, CA, USA.